|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600127213 |
|
最近更新日期: Date of Last Refreshed on: |
2026-06-26 15:46:15 |
|
注册时间: Date of Registration: |
2026-06-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
TAVR术后冠脉入路体外验证研究 |
|
Public title: |
Post-TAVR Coronary Approach Extracorporeal Verification Study |
|
注册题目简写: |
|
|
English Acronym: |
Post-TAVR Coronary Approach Extracorporeal Verification Study |
|
研究课题的正式科学名称: |
主动脉瓣狭窄患者长自膨瓣TAVR术后可能冠脉入路的体外验证性研究 |
|
Scientific title: |
An in vitro validation study on the possibility of coronary artery access after self-expanding valve TAVR in patients with aortic stenosis |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
冯沅 |
研究负责人: |
冯沅 |
|
Applicant: |
Feng Yuan |
Study leader: |
Feng Yuan |
|
申请注册联系人电话: Applicant telephone: |
+86 18080602174 |
研究负责人电话:
Study leader's |
+86 28 85422114 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
fynotebook@hotmail.com |
研究负责人电子邮件: Study leader's E-mail: |
fynotebook@hotmail.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国四川省成都市武侯区国学巷37号 |
研究负责人通讯地址: |
中国四川省成都市武侯区国学巷37号 |
|
Applicant address: |
37 Guoxue Alley, Wuhou District, Chengdu, Sichuan, China |
Study leader's address: |
37 Guoxue Alley, Wuhou District, Chengdu, Sichuan, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
四川大学华西医院 |
||
|
Applicant's institution: |
West China Hospital of Sichuan University |
||
|
研究负责人所在单位: |
四川大学华西医院 |
||
|
Affiliation of the Leader: |
West China Hospital of Sichuan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2026年审(519)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川大学华西医院生物医学伦理审查委员会 |
||
|
Name of the ethic committee: |
Ethics Committee on Biomedical Research West China Hospital of Sichuan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-05-26 00:00:00 | ||
|
伦理委员会联系人: |
李娜 |
||
|
Contact Name of the ethic committee: |
Li Na |
||
|
伦理委员会联系地址: |
中国四川省成都市武侯区国学巷37号 |
||
|
Contact Address of the ethic committee: |
37 Guoxue Alley, Wuhou District, Chengdu, Sichuan, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 28 85422654 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
188974152@qq.com |
|
研究实施负责(组长)单位: |
四川大学华西医院 |
||||||||||||||||||||||
|
Primary sponsor: |
West China Hospital of Sichuan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国四川省成都市武侯区国学巷37号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
37 Guoxue Alley, Wuhou District, Chengdu, Sichuan, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
上海微创心通医疗科技有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Shanghai MicroPort CardioFlow Medtech Co., Ltd. |
||||||||||||||||||||||
|
研究疾病: |
经导管主动脉瓣置换术 |
||||||||||||||||||||||
|
Target disease: |
Transcatheter aortic valve replacement surgery |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
评估症状性重度AS患者TAVR术后主动脉根部解剖3D打印个体化模型冠状动脉入路的可及性及其操作难度 |
||||||||||||||||||||||
|
Objectives of Study: |
Evaluate the accessibility and operational difficulty of the coronary artery approach in the 3D printed individualized model of the aortic root anatomy for symptomatic severe AS patients after TAVR surgery |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 植入的人工瓣膜位置无明显异常; 2. 因重度AS病变而已经完成了TAVI并且有术后CT的患者; 3. TAVR术后预期寿命大于1年。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. The position of the implanted artificial valve shows no obvious abnormalities; 2. Patients who have undergone TAVI due to severe AS and have undergone postoperative CT; 3. The expected lifespan after TAVR is greater than one year. |
||||||||||||||||||||||
|
排除标准: |
1. 首次TAVR时同期植入两个或以上THV; 2. TAVR术前或术后未行主动脉根部增强MSCT检查; 3. 主动脉根部增强MSCT图像质量差,例如存在明显伪影、造影剂对比度过低或图像噪声过重等情况,影响数据分析; 4. 无法下载多层螺旋CT(multislice computed tomography,MSCT)DICOM格式数据以进行离线分析。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Concurrent implantation of two or more thoracoabdominal valves (THV) during the first TAVR procedure; 2. No enhanced MSCT examination of the aortic root was performed before or after the TAVR procedure; 3. The quality of the enhanced MSCT images of the aortic root is poor, such as presence of obvious artifacts, low contrast of the contrast agent, or excessive image noise, which affects data analysis; 4. Unable to download the DICOM format data of multi-slice computed tomography (MSCT) for offline analysis. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-07-01 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-07-02 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
Excel表格登记 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Excel spreadsheet |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |